Skip to main
ETNB
ETNB logo

89bio Inc (ETNB) Stock Forecast & Price Target

89bio Inc (ETNB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

89bio Inc., a clinical-stage biopharmaceutical company, is advancing its lead product candidate, pegozafermin, targeted at addressing critical liver and cardio-metabolic diseases, specifically nonalcoholic steatohepatitis and severe hypertriglyceridemia. The ongoing clinical trials for pegozafermin are generating positive preliminary results that suggest significant efficacy, thereby enhancing the company's prospects for future commercialization. Additionally, robust liquidity positions and strategic partnerships may support the continuation of its development pipeline, bolstering investor confidence in the company's long-term growth potential.

Bears say

89bio Inc faces significant risks that negatively impact its investment outlook, particularly related to the commercial potential of its product candidate, pegozafermin. Key concerns include the possibility of failing to meet peak revenue estimates due to limitations in market size, penetration, and pricing strategies, which could hinder the company's financial performance. Additionally, the inability to secure adequate capital resources for ongoing operations and development raises further fears about the viability of its commercialization efforts.

89bio Inc (ETNB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 89bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 89bio Inc (ETNB) Forecast

Analysts have given 89bio Inc (ETNB) a Buy based on their latest research and market trends.

According to 8 analysts, 89bio Inc (ETNB) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

89bio Inc (ETNB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.